Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
Delayed Nyse  -  04:00 2022-12-07 pm EST
72.58 USD   +0.43%
08:06aMizuho Slashes Price Target on Edwards Lifesciences to $85 From $100, Reiterates Buy Rating
MT
12/06Stifel Downgrades Edwards Lifesciences to Hold From Buy, Adjusts Price Target to $75 From $95
MT
12/05North American Morning Briefing: Fed Tightening -3-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Edwards Lifesciences Corporation's Transcatheter Edge-To-Edge Repair Receives FDA Approval

09/15/2022 | 09:03am EST

Edwards Lifesciences Corporation announced that its PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR). The PASCAL Precision system, with its independent grasping, atraumatic clasp and closure, and ability to elongate, enables safe and effective treatment for patients with DMR. Engineered with an intuitive catheter and handle, the system is designed for maneuverability and stability, enabling precise navigation and implant delivery. Data from the CLASP IID pivotal trial, the first randomized controlled trial to directly compare two contemporary TEER therapies, will be presented as a late-breaking clinical science session on Sept.

17 at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. The PASCAL Precision system is one of multiple transcatheter repair or replacement therapies in development by Edwards that are designed to address mitral and tricuspid valve disease, and the company's first such therapy approved for DMR in the US. Edwards is committed to transforming the treatment of mitral and tricuspid patients, supported by a robust body of clinical evidence.

The commercial opportunity related to this approval is factored into 2022 financial expectations. Transcatheter Edge-to-Edge Repair (TEER) of the mitral valve is used in the treatment of mitral regurgitation. TEER approximates the anterior and posterior mitral valve leaflets by grasping them with a clipping device in an approach similar to a treatment developed in cardiac surgery called the Alfieri stitch.


ę S&P Capital IQ 2022
All news about EDWARDS LIFESCIENCES CORPORATION
08:06aMizuho Slashes Price Target on Edwards Lifesciences to $85 From $100, Reiterates Buy Ra..
MT
12/06Stifel Downgrades Edwards Lifesciences to Hold From Buy, Adjusts Price Target to $75 Fr..
MT
12/05North American Morning Briefing: Fed Tightening -3-
DJ
12/02Wolfe Research Downgrades Edwards Lifesciences to Peer Perform From Outperform
MT
11/28RBC Cuts Price Target on Edwards Lifesciences to $105 From $118 Amid Foreign Exchange I..
MT
11/28Edwards Lifesciences Says Tricuspid Valve Replacement Study Showed Survival of 90.1% Af..
MT
11/27Edwards announces one-year data on transfemoral transcatheter tricuspid valve replaceme..
PR
11/27Edwards Lifesciences Corporation Announces One-Year Data on Transfemoral Transcatheter ..
CI
11/15Insider Sell: Edwards Lifesciences
MT
11/03Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $73 From $97, Maintains N..
MT
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2022 5 359 M - -
Net income 2022 1 495 M - -
Net cash 2022 1 120 M - -
P/E ratio 2022 30,5x
Yield 2022 -
Capitalization 44 873 M 44 873 M -
EV / Sales 2022 8,16x
EV / Sales 2023 7,50x
Nbr of Employees 15 700
Free-Float 95,1%
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 72,58 $
Average target price 93,73 $
Spread / Average Target 29,1%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EDWARDS LIFESCIENCES CORPORATION-43.00%44 682
THERMO FISHER SCIENTIFIC-17.49%216 935
DANAHER CORPORATION-19.35%193 165
INTUITIVE SURGICAL, INC.-25.88%94 110
BOSTON SCIENTIFIC CORPORATION6.92%64 683
SIEMENS HEALTHINEERS AG-25.17%57 995